Universal Health Servs 주식 (NYSE: UHS)

에 대한 최신 뉴스 Universal Health Servs (NYSE:UHS) 주식

Universal Health Servs

Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.

Universal Health Services

News

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Universal Health Services, Inc. Common Stock

Universal Health Services Inc

Axonics, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axnx#NASDAQ">AXNX</a>) has received regulatory approval from the Therapeutic Goods Administration&nbsp;to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia.
This cutting-edge device features a 20-year functional life and reduces recharge frequency to once every 6 to 10 months for only one hour.&nbsp;The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15). Paired with intuitive remote control and enhanced MRI compatibility, the R20 builds on Axonics&#39; commitment to improving incontinence care.
The Axonics R15 is designed to treat bladder and bowel dysfunctions, such as overactive bladder and fecal incontinence. By delivering electrical stimulation to the sacral nerves, this implantable neurostimulator helps regulate control, providing patients with effective and lasting relief.
Axonics began commercial activities for its SNM systems in Australia in March 2023. By May 2024, it received TGA approval to market its F15 recharge-free SNM system. Axonics also offers Bulkamid, a hydrogel used to treat female stress urinary incontinence in Australia.
<h2>Likely Trend of AXNX Stock Following the News</h2>
Following the news release, shares of AXNX declined 0.1% to $69.53 at yesterday&#39;s closing.
Shares of Axonics have gained 11.7% year to date against the industry&#39;s 9.1% decline. The S&amp;P 500 has risen 19.9% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/10/79516.jpg?v=1511961268" />
Image Source: Zacks Investment Research
Despite the recent price decline, the TGA approval for Axonics&#39; R20 rechargeable SNM&nbsp;system reflects a positive sentiment for the company, as it continues to provide long-lasting, effective therapies for adults with overactive bladder and fecal incontinence. Additionally, its Bulkamid hydrogel offers durable relief for women with stress urinary incontinence, addressing a significant global need.
<h2>Importance of Axonics&#39; TGA Approval for R20 Rechargeable SNM</h2>
The TGA&#39;s approval of Axonics&#39; R20 marks a significant advancement in the treatment of bladder and bowel dysfunction for Australian patients. With a lifespan of 20 years and minimal recharging needs, the R20 offers durable symptom relief and enhanced convenience. This fourth-generation device reflects Axonics&#39; innovative approach and further strengthens the company&#39;s position in the Australian SNM market following the approval of the F15 recharge-free system earlier this year. The launch of the R20 demonstrates Axonics&#39; ongoing dedication to providing best-in-class incontinence therapies.
Axonics plans to begin selling its R20 rechargeable SNM system to Australian customers in November, following the recent regulatory approval.
<h2>Market Prospects Favoring AXNX</h2>
Per a report in Grand View Research, the global&nbsp;neuromodulation devices market size is estimated to be worth $5.8 billion in 2024. It is anticipated to reach $10.4 billion by 2030 at a CAGR of 10.2%.&nbsp;
The robust growth is likely to be driven by the rise in the prevalence of lifestyle diseases such as chronic pain and depression, an increase in the number of neurological diseases and increased investment by private players in studying neurological disorders.&nbsp;
<h2>Zacks Rank &amp; Key Picks</h2>
Currently, Axonics carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Services&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), ATI Physical Therapy (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atip#NYSE">ATIP</a>) and Aveanna Healthcare&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avah#NASDAQ">AVAH</a>). While Universal Health Services sports a Zacks Rank #1 (Strong Buy), ATI Physical Therapy and Aveanna Healthcare&nbsp;carry a Zacks Rank #2 (Buy) each at present.
Universal Health Services has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Services has gained 41.1% compared with the industry&#39;s&nbsp;34.8% growth year to date.
ATI Physical Therapy&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.25%.
ATIP&#39;s shares have gained 5.5% year to date compared with the&nbsp;industry&#39;s&nbsp;18.6% growth.
Aveanna Healthcare&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 47.5%.
AVAH&#39;s shares have surged 104.5% year to date compared with the industry&#39;s&nbsp;15.7% growth.
<a href="https://www.zacks.com/stock/news/2342710/axonics-shares-fall-despite-australia-s-approval-for-r20-snm-device?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2342710">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Government

Large Cap

Mid Cap

Regulations

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ATIP

AVAH

AXNX

Axonics Shares Fall Despite Australia's Approval for R20 SNM Device

The Dow Jones Industrial Average inched up higher on Friday, setting a new record after a strong week, driven by the Federal Reserve&#39;s first rate cut in four years. The Dow rose by 38.16 points, or 0.09%, to close at 42,063.36. In contrast, the S&amp;P 500 slipped 0.19% to 5,702.55, and the Nasdaq Composite fell 0.36% to finish at 17,948.32. This movement came after a midweek rally, during which the Dow surpassed the 42,000 mark and the S&amp;P 500 hit a key milestone above 5,700. Despite Friday&#39;s slight pullbacks, all three major indexes posted weekly gains.
The Fed&#39;s decision to lower interest rates by 50 basis points spurred a buying spree on Thursday. However, markets steadied on Friday as investors stepped back from the prior day&#39;s surge. Going forward, the market will engage with a blend of economic indicators, including key releases, political developments and corporate earnings reports, all of which could trigger volatility. In this environment, value stocks stand out as a compelling investment option. Typically trading below their intrinsic value, these stocks offer a margin of safety during market fluctuations.
When evaluating value stocks, one of the most effective valuation metrics is the Price to Cash Flow (P/CF) ratio. This metric measures the market price of a stock relative to the cash flow the company generates on a per-share basis. A lower P/CF ratio indicates that the stock is trading at a better value, offering strong cash generation potential relative to its price. Here are four companies &mdash; Universal Health Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), Carriage Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/csv#NYSE">CSV</a>), AXIS Capital Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axs#NYSE">AXS</a>) and EnerSys (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ens#NYSE">ENS</a>) &mdash; that boast low P/CF ratios, making them strong contenders for value-seeking investors.
<h2>Price to Cash Flow Ratio Reveals Financial Health</h2>
Questions may arise as to why we are considering the P/CF valuation metric when the most widely used metric is Price/Earnings (or P/E). Well, what makes P/CF stand out is that operating cash flow adds back non-cash charges such as depreciation and amortization to net income, truly reflecting the financial health of a company.
Analysts caution that a company&#39;s earnings are subject to accounting estimates and management manipulation. However, cash flow is reliable. It is net cash flow that reveals how much money a company is actually generating and how effectively management is putting the same to use.
A positive cash flow indicates an increase in the company&#39;s liquid assets. This gives the company the means to settle debt, shell out for its expenses, reinvest in its business, endure downturns, and finally pay back its shareholders. Then again, a negative cash flow implies a decline in the company&#39;s liquidity, which in turn lowers its flexibility to support these moves.
<h2>What&#39;s the Best Value Investing Strategy?</h2>
An investment decision solely based on the P/CF metric may not fetch the desired results. To identify stocks that are trading at a discount, you should expand your search criteria and also consider the price-to-book ratio, price-to-earnings ratio, and price-to-sales ratio. Adding a favorable Zacks Rank and a Value Score of A or B to your search criteria should lead to even better results as these eliminate the chance of falling into a value trap.
Here are the parameters for selecting true-value stocks:
P/CF less than or equal to X-Industry Median.
Price greater than or equal to 5: The stocks must all be trading at a minimum of $5 or higher.
Average 20-Day Volume greater than 100,000: A substantial trading volume ensures that the stock is easily tradable.
P/E using (F1) less than or equal to X-Industry Median: This parameter shortlists stocks that are trading at a discount or are equal to their peers.
P/B less than or equal to X-Industry Median: A lower P/B compared with the industry average implies that there is enough room for the stock to gain.
P/S less than or equal to X-Industry Median: The P/S ratio determines how a stock price compares to the company&#39;s sales &mdash; the lower the ratio, the more attractive the stock is.
PEG less than 1: The ratio is used to determine a stock&#39;s value by taking the company&#39;s earnings growth into account. The PEG ratio portrays a more complete picture than the P/E ratio. A value of less than 1 indicates that the stock is undervalued and that investors need to pay less for a stock that has robust earnings growth prospects.
Zacks Rank less than or equal to 2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.
Value Score of less than or equal to B: Our research shows that stocks with a Style Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best upside potential.
Here are four of the 11 low P/CF stocks that qualified the screening:
Universal Health Services, one of the nation&#39;s largest hospital companies, operating through its subsidiaries, acute care hospitals, behavioral health facilities and ambulatory centers, sports a Zacks Rank #1. The company has a trailing four-quarter earnings surprise of 14.6%, on average.
The Zacks Consensus Estimate for Universal Health Services&#39; current financial year sales and earnings per share suggests growth of 9.8% and 51%, respectively, from the year-ago period. Universal Health Services has a Value Score of A. Shares of UHS have rallied 85.8% in the past year.
Carriage Services, a leading provider of funeral and cemetery services and merchandise in the United States, carries a Zacks Rank #1. The company has a trailing four-quarter earnings surprise of 17%, on average.
The Zacks Consensus Estimate for Carriage Services&#39; current financial year sales and EPS suggests growth of 3.7% and 6.9%, respectively, from the year-ago period. CSV has a Value Score of B. Shares of CSV have risen 11.5% in the past year.
AXIS Capital Holdings, a global specialty underwriter and provider of insurance and reinsurance solutions, sports a Zacks Rank #1. The company has a trailing four-quarter earnings surprise of 94.6%, on average.
The Zacks Consensus Estimate for AXIS Capital&#39;s current financial year sales and EPS suggests growth of 7.2% and 8.7%, respectively, from the year-ago period. AXS has a Value Score of A. Shares of AXS have advanced 34.4% in the past year.
EnerSys, the global leader in stored energy solutions for industrial applications, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 1.5%, on average.
The Zacks Consensus Estimate for EnerSys&#39; current financial year sales and EPS suggests growth of 4.7% and 7.1%, respectively, from the year-ago period. ENS has a Value Score of A. Shares of ENS have increased 6.3% in the past year.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
<a href="https://www.zacks.com/stock/news/2340101/4-top-stocks-to-buy-for-value-investing-after-fed-rate-cut?cid=CS-BENZ-FT-analyst_blog|rw-2340101" style="font-size: 13px;">To read this article on Zacks.com click here.</a>

Federal Reserve

4 Top Stocks to Buy for Value Investing After Fed Rate Cut

GE HealthCare Technologies&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gehc#NASDAQ">GEHC</a>) MIM Software recently announced the receipt of FDA clearance for performing Centiloid scaling for positron emission tomography (PET)-based amyloid imaging analysis and quantification.
With MIMneuro, a vendor-neutral solution, this new Centiloid scale tool is likely to be able to assist physicians in more accurately determining the density of amyloid plaque in a patient&#39;s brain. Amyloid PET radiotracers help visualize amyloid plaque density in patients being evaluated for Alzheimer&#39;s disease.
<h2>Likely Trend of GEHC Stock Following the News</h2>
Following the announcement, shares of the company moved nearly 1.7% north to $88.53 at yesterday&#39;s close.
GE HealthCare is one of the leading providers of medical technology, pharmaceutical diagnostics, and digital solutions with a focus on precision care. In March, GE Healthcare acquired MIM Software, which added AI-based solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics and research organizations worldwide. Owing to the strong potential for the diagnostic imaging market, we expect the market sentiment to remain positive around this news.
Meanwhile, GEHC currently has a market capitalization of $39.63 billion. It has an earnings yield of 4.91% is much higher than the industry&#39;s yield of negative (7.12)%. In the last reported quarter, GEHC delivered an earnings surprise of 2.04%.
<h2>More on the GEHC&#39;s Centiloid Scaling Tool</h2>
A significant number of people in the United States develop dementia, with Alzheimer&#39;s disease accounting for 60-80% of dementia cases. The condition affects memory, thinking and behavior, and symptoms typically start with mild cognitive impairment and eventually grow severe enough to interfere with daily tasks. A characteristic feature of this condition is the build-up of beta-amyloid protein in the brain, which is connected to tissue loss and cell death.
In order to assist physicians in identifying potential patients for amyloid-targeting therapies, PET imaging makes it possible to visualize and quantify amyloid protein. A global consortium of physicians and scientists created the Centiloid scale with the goal of harmonizing quantitative amyloid imaging analysis throughout radiotracers and organizations.
GE HealthCare&#39;s MIM Software now offers MIMneuro with Centiloid scaling, leveraging an automated workflow to help guide users through generating and understanding the quantitative result. The software takes the PET amyloid images, provides clinicians instructions to automatically generate quantitative results, and presents the data in a standardized report for clinicians to review alongside the images. As a result, clinicians can more easily access the quantitative data they need to evaluate patients.
MIMneuro with Centiloid scaling is the latest addition to GE HealthCare&#39;s comprehensive suite of products and solutions, which span the Alzheimer&#39;s disease care pathway from diagnosis through treatment monitoring.
<h2>Favorable Industry Prospects for GEHC</h2>
Per a report by Future Market Insight, the global brain imaging and neuroimaging market was estimated to be $13.7 billion in 2023 and is anticipated to surpass $22.4 billion by 2033 at a CAGR of 5.1%. The brain imaging and neuroimaging market is primarily driven by the rising incidence and prevalence of neurological disorders, increased awareness of neurodegenerative diseases, an increase in traumatic brain injuries, and increased applications of brain imaging and neuroimaging in clinical trials.
Given the market potential, the latest FDA clearance of MIM Software&#39;s Centiloid Scaling Tool is likely to provide a boost to GEHC&#39;s business.
<h2>GEHC&#39;s Notable Developments</h2>
In August, GEHC announced the receipt of the CE mark for its Vscan Air SL wireless handheld ultrasound system with Caption AI. The company also received the CE mark for the use of ECG-less cardiac computed tomography scanning on its Revolution Apex platform.
The company also collaborated with the University of California San Diego School of Medicine. The tie-up aims to investigate advanced magnetic resonance imaging protocols and techniques for female-specific diseases and conditions of the pelvis and develop comprehensive educational materials for clinicians.
<h2>GEHC&#39;s Price Performance</h2>
In the past six months, GEHC shares have lost 2.6% compared with the industry&#39;s decline of 12.4%. The S&amp;P 500 has gained 7.6% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/51/78442.jpg?v=1728486434" />
Image Source: Zacks Investment Research
<h2>GE HealthCare&#39;s Zacks Rank &amp; Stocks to Consider</h2>
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 56.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;48.1% rise.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 13.9% so far this year compared with the&nbsp;industry&#39;s&nbsp;17.9% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 27.4% so far this year compared with the&nbsp;industry&#39;s&nbsp;17% growth.
<a href="https://www.zacks.com/stock/news/2338704/gehc-stock-rises-as-fda-clears-mim-software-s-centiloid-tool?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2338704">To read this article on Zacks.com click here.</a>

GEHC

GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool

The Company priced the offering of&nbsp;$500 million&nbsp;aggregate principal amount of its&nbsp;4.625%&nbsp;senior secured notes due 2029 (the &quot;2029 Notes&quot;) and&nbsp;$500 million&nbsp;aggregate principal amount of its&nbsp;5.050%&nbsp;senior secured notes due 2034 (the &quot;2034 Notes&quot;, and together with the 2029 Notes, the &quot;Notes&quot;). The Notes will pay interest semi-annually in arrears, on&nbsp;April 15th&nbsp;and&nbsp;October 15th&nbsp;of each year, beginning on&nbsp;April 15, 2025. The 2029 Notes will mature on&nbsp;October 15, 2029&nbsp;and the 2034 Notes will mature on&nbsp;October 15, 2034, unless earlier redeemed or repurchased.&nbsp;

Reported Earlier, Universal Health Services Prices $1B Senior Secured Notes Offering With Maturities In 2029 And 2034

Solventum Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/solv#NYSE">SOLV</a>) recently announced the launch of the V.A.C. Peel and Place Dressing, an integrated dressing and drape that can be applied quickly&nbsp;and worn by patients for up to seven days.
Traditional dressings for negative pressure wound therapy typically take more than twice as long to apply, require a multi-step process of measuring and cutting separate foam and adhesive components, and may need to be changed at least three times a week.
The latest launch by SOLV is likely to solve the persisting issues of traditional dressings for negative pressure wound therapy, making it more accessible and less painful. The V.A.C. Peel and Place Dressing is an essential innovation in wound care that has the potential to improve outcomes, save both time and money and enhance the overall patient and clinician experience.
Due to the factors mentioned above, the product is likely to witness substantial demand in the field of negative pressure wound therapy and contribute to the top-line growth of the company, thus driving the share price of SOLV higher.
<h2>More on the SOLV&#39;s V.A.C Peel and Place Dressing</h2>
The latest development in V.A.C.&nbsp;Therapy is the new V.A.C.&nbsp;Peel and Place Dressing. Due to its integrated dressing and drape design, dressing application and changes are easier to perform, requiring less time and training. Moreover, it has an integrated non-adherent, perforated layer that reduces tissue ingrowth and lessens discomfort when removing the dressing.
The V.A.C. Peel and Place Dressing is suggested for use on wounds up to 6 cm deep, covering chronic, acute, traumatic, subacute, and dehisced wounds. Additionally, it can be used on partial thickness burns, pressure ulcers (such as those caused by diabetes), venous insufficiency, flaps, and grafts.
Research has demonstrated that the V.A.C. Peel and Place Dressing can substantially reduce&nbsp;therapy application time. It can also lower hospital bedside expenditures significantly&nbsp;because of fewer dressing changes and lower&nbsp;home nursing visits per week.
V.A.C.&nbsp;Therapy has been linked to noticeably faster wound healing. Over nearly three decades, it has been used globally to treat more than 10 million wounds. However, a rise in wound numbers is increasing due to aging populations and the incidence of chronic illnesses such as obesity and diabetes. The V.A.C. Peel and Place Dressing enables V.A.C. Therapy to be used on a wider range of patients across the continuum of care in both acute and post-acute settings.
The product is available now in the United States and Canada. Additional global regulatory submissions and approvals are pending.
<h2>Favorable Industry Prospects for SOLV</h2>
Per a report by Grand View Research, the global negative pressure wound therapy market size was estimated to be $2.5 billion in 2023 and is expected to witness a CAGR of 6.6% from 2024 to 2030.
Given the market potential, SOLV&#39;s V.A.C Peel and Place Dressing is likely to provide a boost to SOLV&#39;s business.
<h2>SOLV&#39;s&nbsp;Price Performance</h2>
In the past six months, SOLV shares have lost 1.1% compared with the industry&#39;s decline of 1.3%. The S&amp;P 500 has gained 6.4% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9f/77363.jpg?v=2024522534" />
Image Source: Zacks Investment Research
<h2>SOLV&#39;s Zacks Rank and Stocks to Consider</h2>
Currently, SOLV has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>)&nbsp;and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries presently carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 56.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;48.1% rise.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 13.9% so far this year compared with the&nbsp;industry&#39;s&nbsp;17.9% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 27.4% so far this year compared with the&nbsp;industry&#39;s&nbsp;17% growth.
<a href="https://www.zacks.com/stock/news/2334834/solventum-shares-may-gain-on-the-launch-of-its-new-v-a-c-therapy?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2334834">To read this article on Zacks.com click here.</a>

Health Care

Events

SOLV

Solventum Shares May Gain on the Launch of Its New V.A.C Therapy

Shares of The Cigna Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ci#NYSE">CI</a>) have gained 25.6% in the past year compared with the industry&#39;s 18.2% growth. The Medical sector and the S&amp;P 500 composite index have rallied 9.3% and 21.2%, respectively, in the same time frame. CI has been well-poised for growth on the back of a sound membership base, solid Evernorth unit, acquisitions and expanding cash reserves.&nbsp;
Currently priced at $357.40, the stock is just 3.6% below its 52-week high of $370.64. This proximity underscores investor confidence and market optimism about Cigna&#39;s prospects.&nbsp;
The health insurer, presently carrying a Zacks Rank #3 (Hold), has an impressive record of beating estimates in each of the trailing four quarters, the average surprise being 3.83%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a8/77228.jpg?v=810613562" />
Image Source: Zacks Investment Research
<h2>Robust Growth Prospects of CI Stock</h2>
The Zacks Consensus Estimate for Cigna&#39;s 2024 earnings is pegged at $28.48 per share, which indicates a 13.5% increase from the 2023 figure. The consensus mark for revenues is $239.1 billion, which implies 22.4% growth from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for 2025 earnings is pegged at $31.80 per share, which implies an 11.7% improvement from the 2024 estimate. The consensus mark for revenues is $246.5 billion, implying a 3.1% rise from the 2024 estimate.
<h2>Cigna&#39;s Business Tailwinds</h2>
Cigna&#39;s performance is underscored its strong growth platforms, Evernorth and Cigna Healthcare. Evernorth is propelled by a range of specialty pharmacy services, significantly enhancing pharmacy revenues for the parent company. Pharmacy revenues saw a 31.8% year-over-year increase in the first half of 2024.&nbsp;
Conversely, Cigna Healthcare is strengthened by its sound customer base across the U.S. Healthcare business. This segment anticipates long-term average annual adjusted earnings growth in the band of 7-10%.&nbsp;
An expanding customer base leads to higher premiums, a critical revenue source for health insurers. As of June 30, 2024, Cigna served 19 million medical customers. The aging U.S. population is likely to drive continuous demand for its Medicare plans in the days ahead. In addition to premium growth, Cigna Healthcare benefits from ongoing product enhancements and new or extended partnerships with prominent healthcare systems.
Cigna strategically acquires companies to bolster its solutions and capabilities, broaden its geographical reach and reinforce its market presence. In alignment with its focus on high-growth platforms, it has divested its non-core health units. A robust cash balance and sufficient cash generation abilities allow the company to invest in business expansion and strategically allocate capital for share buybacks and dividends. Over the next five years, management anticipates cash flows of approximately $60 billion.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the Medical space are Universal Health Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>) and HCA Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hca#NYSE">HCA</a>). Universal Health currently sports a Zacks Rank #1 (Strong Buy), and Ensign Group and HCA Healthcare carry a Zacks Rank #2 (Buy).
Universal Health&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 14.58%. The consensus estimate for UHS&#39; 2024 earnings indicates a rise of 51% from the year-ago number. The consensus mark for revenues indicates growth of 9.8% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for UHS&#39; earnings has moved 15% north in the past 30 days. Shares of Universal Health have gained 73.7% in the past year.
Ensign Group&#39;s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.40%. The consensus estimate for ENSG&#39;s 2024 earnings indicates a rise of 14.1% from the year-ago number. The consensus mark for revenues implies an improvement of 13.1% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for ENSG&#39;s earnings has moved 0.7% north in the past 60 days. Shares of Ensign Group have risen 59.9% in the past year. &nbsp;
HCA Healthcare&#39;s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed the mark once, the average surprise being 8.24%. The consensus estimate for HCA&#39;s 2024 earnings indicates an improvement of 18.2% from the year-ago figure. The consensus mark for revenues implies growth of 8.9% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for HCA&#39;s earnings has moved 1.2% north in the past seven days. Shares of HCA Healthcare have rallied 42% in the past year.
<a href="https://www.zacks.com/stock/news/2334211/cigna-stock-gains-26-in-a-year-what-lies-ahead-for-investors?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2334211">To read this article on Zacks.com click here.</a>

Dividends

Buybacks

Management

ENSG

Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?

RBC Capital analyst Ben Hendrix maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Sector Perform and raises the price target from $189 to $222.

Price Target

RBC Capital Maintains Sector Perform on Universal Health Servs, Raises Price Target to $222

The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>) announced that it has bought the operations of a nursing facility in Overland Park, KS. It has also acquired the operations of seven nursing facilities in Colorado. All these buyouts (with long-term, triple net leases) had an effective date of Sept. 1, 2024.&nbsp;
The 102-bed unit in Kansas, named Prairie Ridge Health and Rehabilitation, boosts ENSG&#39;s footprint in the state. The acquisition comes at an opportune time, as the company is experiencing significant growth in the state over the last year.
The series of acquisitions in Colorado includes the 106-bed Desert Willow Health and Rehabilitation Center in Pueblo, 133-bed Junction Creek Health and Rehabilitation Center in Durango, 104-bed Pelican Pointe Health and Rehabilitation Center in Windsor, 100-bed Riverbend Health and Rehabilitation Center in Loveland, 100-bed Broadview Health and Rehabilitation Center in Greeley, 107-bed Westlake Lodge Health and Rehabilitation Center in Greeley and 110-bed Linden Place Health and Rehabilitation Center in Longmont.
The acquisition deals have increased Ensign&#39;s portfolio to encompass 323 healthcare operations spanning 14 states. Of the total, 29 also have senior living operations. The company, along with its subsidiaries like Standard Bearer, now owns 122 real estate properties.
ENSG boasts a strong inorganic growth story. The company remains committed to pursuing opportunities for acquiring real estate and leasing both successful and struggling skilled nursing, senior living and other healthcare-related operations. As the number of facilities rises, revenues from skilled services are expected to increase, supported by higher occupancy rates and patient days, indicating robust growth in profits and the top line. This is reflected in the estimates.
<h2>ENSG&#39;s 2024 Estimates</h2>
The Zacks Consensus Estimate for Ensign&#39;s 2024 earnings indicates 14.1% year-over-year growth to $5.44 per share. It beat earnings estimates in each of the past four quarters, with an average surprise of 1.4%. Also, the consensus mark for 2024 revenues indicates a 13.1% jump from a year ago.
<h2>Price Performance</h2>
Shares of Ensign have jumped 23% in the past three months compared with the industry&#39;s 20.9% growth.
<h2>Zacks Rank &amp; Other Key Picks</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ff/76571.jpg?v=2074871970" />
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #2 (Buy). Investors can look at some other top-ranked stocks in the broader Medical&nbsp;space, like Universal Health Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), Tenet Healthcare Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/thc#NYSE">THC</a>) and Quest Diagnostics Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>). While Universal Health and Tenet Healthcare currently sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2.
The Zacks Consensus Estimate for Universal Health Services&#39; 2024 bottom line suggests 50.8% year-over-year growth. UHS witnessed two upward estimate revisions over the past month against no movement in the opposite direction. It beat earnings estimates in each of the last four quarters, with the average surprise being 14.6%.
The Zacks Consensus Estimate for Tenet Healthcare&#39;s 2024 bottom line is pegged at $10.70 per share, which indicates 53.3% growth from a year ago. During the past month, THC witnessed two upward estimate revisions against none in the opposite direction. It beat earnings estimates in each of the last four quarters, with the average surprise being 58.5%.
The Zacks Consensus Estimate for Quest Diagnostics&#39; 2024 full-year earnings implies a 2.1% increase from the year-ago reported figure. DGX beat earnings estimates in each of the last four quarters, with an average surprise of 3.3%. The consensus mark for its current-year revenues is pegged at $9.6 billion, which indicates a 3.3% year-over-year increase.
<a href="https://www.zacks.com/stock/news/2331595/ensign-adds-8-facilities-in-kansas-colorado-to-expand-footprint?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2331595">To read this article on Zacks.com click here.</a>

Ensign Adds 8 Facilities in Kansas & Colorado to Expand Footprint

Shares of Butterfly Network (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NYSE">BFLY</a>) closed 26.9% higher on Sept. 4 after the company announced the commercial launch of its third-generation handheld point-of-care ultrasound system, Butterfly iQ3, in Europe. Investors are likely upbeat about the news due to the strong uptake of Butterfly iQ3 in the U.S. market following its February launch.
Butterfly iQ3 received EU MDR certification in March and is fully compliant with the Restriction of Hazardous Substances Directive. The device will currently be available in all European countries and the United Kingdom. It was launched in Canada during the second quarter. The company is now applying for regulatory approval for iQ3 in additional regions.
The Butterfly iQ3 is the company&#39;s most advanced portable ultrasound device in its portfolio which includes the second-generation iQ+ device. The Butterfly iQ3 uses BFLY&#39;s most advanced P4.3 chip that has double the processing power compared to iQ+ for best-in-class image quality, new advanced 3D imaging tools for easier use and a smaller, more ergonomic design. Moreover, the higher selling price of the device compared to iQ+ should accelerate the revenue growth rate.
BFLY&#39;s shares have gained 39.9% so far this year, significantly outperforming the industry&#39;s decline of 13.5% on the back of the rising adoption of Butterfly iQ3 in the U.S. market. The S&amp;P 500 Index has gained 15.9% in the same period.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d3/76630.jpg?v=1658840067" /> 
Image Source: Zacks Investment Research
<h2>US Performance of BFLY&#39;s iQ3</h2>
Butterfly Network&#39;s 16% top-line growth in the second quarter was primarily driven by robust uptake of Butterfly iQ3 in the United States and additional sales from launch in Canada.&nbsp;Of the company&#39;s total online orders, 74% were for iQ3 during the quarter. iQ3 represented 89% of sales across all channels in Canada. Moreover, the company initiated a competitive device upgrade in the second quarter, allowing customers to turn their old non-butterfly product into a new iQ3. This represents an additional growth opportunity for the company as it upgraded over a thousand probes in the second quarter.
During the second quarter, iQ3 sales represented 50% of total unit sales, with 75% of total units sold in the United States.
<h2>BFLY&#39;s iQ3 to Improve Patient Care</h2>
The company&#39;s new advanced 3D capabilities, iQ Slice and iQ Fan for Butterly iQ3 make image capturing easier. iQ Slice helps to capture up to 46 ultrasound slices at a time across a wide angle. The imaging mode is designed to make it easier and faster to acquire excellent images without skilled maneuvering. On the other hand, iQ Fan is a dedicated lung tool that reduces the movements necessary to capture information and make informed clinical decisions.
These two new features come with Butterfly&#39;s existing robust feature list of more than 20 anatomical presets, six imaging modes and a collection of artificial intelligence, advanced imaging tools and a rich set of Calculation tools.
Apart from its rich features, Butterfly iQ3&#39;s smaller and ergonomic design is fueling its strong adoption in the United States and Canada, which is likely to continue to reflect in European markets as well. The device has a 17% smaller probe face and is 7% shorter in size than iQ+. The new device also comes with a stronger battery with up to 2 hours of thermal run time for outstanding continuous scanning and charges 2.5 times faster.
These features are helping the Butterfly iQ3 device to significantly enhance the echo image quality and the biplane mode for cannulation, which has already proven beneficial in managing patients with challenging IV access.
<div class="chart_embed">
<h3>Butterfly Network, Inc. Price</h3>
<img alt="Butterfly Network, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/75/1725523014.png" style="height:254px; width:572px" title="" />
Butterfly Network, Inc. price | Butterfly Network, Inc. Quote
</div>
<h2>BFLY&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
Butterfly Network currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are&nbsp;Boston Scientific&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>),&nbsp;Apyx Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apyx#NASDAQ">APYX</a>) and&nbsp;Universal Health Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), each carrying a Zacks Rank #2 at present.
Boston Scientific has a long-term estimated growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific&#39;s shares have risen 41.4% year to date compared with the&nbsp;industry&#39;s 12.3% growth.
Apyx Medicalhas an estimated growth rate of 20% for 2025. Its earnings missed estimates in each of the trailing four quarters, delivering a negative average surprise of 25.98%.
Apyx Medical&#39;s shares have lost 49.3% year to date against the&nbsp;industry&#39;s 12.3% growth.
Universal Health Services has a long-term estimated growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.
Universal Health Services&#39; shares have risen 56.1% year to date compared with the&nbsp;industry&#39;s 48% growth.
<a href="https://www.zacks.com/stock/news/2331850/butterfly-network-s-stock-surges-on-iq3-device-launch-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2331850">To read this article on Zacks.com click here.</a>

Penny Stocks

Tech

APYX

BFLY

Butterfly Network's Stock Surges on iQ3 Device Launch in Europe

16 analysts have expressed a variety of opinions on Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Universal Health Servs, presenting an average target of $215.0, a high estimate of $274.00, and a low estimate of $162.00. Surpassing the previous average price target of $193.69, the current average has increased by 11.0%.
<img src="https://www.benzinga.com/files/images/story/2024/1725451236_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Universal Health Servs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$274.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$267.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$229.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$220.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$256.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$198.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$198.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Universal Health Servs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Universal Health Servs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Universal Health Servs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UHS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Universal Health Servs analyst ratings.</a>
<h2>Discovering Universal Health Servs: A Closer Look</h2>
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
<h3>Unraveling the Financial Story of Universal Health Servs</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Universal Health Servs showcased positive performance, achieving a revenue growth rate of 10.13% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.4%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Universal Health Servs's ROE stands out, surpassing industry averages. With an impressive ROE of 4.54%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Universal Health Servs's ROA stands out, surpassing industry averages. With an impressive ROA of 2.06%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.77.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 16 Analyst Ratings Have To Say About Universal Health Servs

Baird analyst Michael Ha maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Outperform and raises the price target from $236 to $274.

Baird Maintains Outperform on Universal Health Servs, Raises Price Target to $274

Tenet Healthcare Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/thc#NYSE">THC</a>) shares have returned 24.6% in the past three months, outperforming both the hospital industry and the S&amp;P 500 Index. Over this timeframe, the industry and the S&amp;P 500 Indexhave gained 20.8% and 6.4%, respectively.&nbsp;
Currently priced at $163.87, the stock is just 1% below its 52-week high. This proximity underscores investor confidence and market optimism about this hospital company&#39;s prospects. Moreover, the stock is trading above its 50-day and 200-day moving averages, signaling strong upward momentum.
<h2>3-Month Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/02/75772.jpg?v=812194338" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Decoding THC&#39;s Bright Prospects</h2>
The growing senior population and increasing prevalence of diseases are expected to drive long-term demand for hospital services. Tenet Healthcare is well-positioned to benefit from this trend through strategic acquisitions and the development of new facilities. These expansion efforts aim to help Tenet capture more market share in a highly fragmented healthcare market, which will boost its adjusted admissions, emergency room visits and hospital surgeries.
Improving labor market conditions and effective staffing solutions are allowing the company to hire more workers and reopen services that were earlier shut down due to pandemic-related challenges. This increased capacity is expected to meet the rising demand for healthcare services. The company&#39;s strong second-quarter results reflect this positive growth trend.
Tenet&#39;s robust Q2 performance led it to raise its 2024 forecast. Net operating revenues from the Hospital segment are now expected to be between $16.3 billion and $16.5 billion, up from the previous range of $15.9 billion to $16.1 billion. Additionally, adjusted EBITDA is now projected to be between $3.825 billion and $3.975 billion, compared to the earlier estimate of $3.5 billion to $3.7 billion.
<h2>THC&#39;s Strategic Efforts</h2>
By the end of the second quarter, Tenet had stakes in 520 ambulatory surgery centers and 24 surgical hospitals. The company expects its transformative efforts to boost margins and free cash flow while creating a diversified business mix that can thrive in any political or regulatory environment. This approach will help reduce risks for investors.
Tenet Healthcare is focusing more on ambulatory surgery centers to tap into the rising demand for outpatient services. By leveraging its partnership with United Surgical Partners International, the company aims to expand its network, enhance operational efficiency, and improve profit margins.
Strategic investments in artificial intelligence-enabled technologies are set to enhance both clinical and administrative workflows, boosting overall efficiency. These advancements will likely reduce costs, shorten patient wait times and significantly improve the patient experience.
Alongside favorable industry trends, THC&#39;s focus on operational efficiency and rising net revenue per caseare expected to drive further profit growth, which is reflected by the revised estimates. Also, it doesn&#39;t shy away from divesting non-core and unprofitable business units to repay debt, maintain financial liquidity and make higher-return investments.
<h2>Estimate Revision Favoring THC Stock</h2>
Reflecting the positive sentiment around Tenet, the Zacks Consensus Estimate for earnings per share has seen upward revisions. The consensus estimate for 2024 adjusted earnings for THC is currently pegged at $10.70 per share, indicating a 53.3% year-over-year surge. The consensus mark for 2025 suggests a further 2.4% jump. It beat earnings estimates in each of the past four quarters, with an average surprise of 58.5%. The consensus estimate for 2024 and 2025 revenues suggests 1.4% and 3.8% year-over-year growth, respectively.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ae/75774.jpg?v=1359469431" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>THC: A Value-Driven Choice</h2>
Despite the recent growth in stock price, Tenet is trading at a discount compared to the industry average. It presents a compelling investment opportunity with its attractive forward 12-month price-to-earnings ratio of 15.07X, lower than the industry average of 16.19X. The company has a Value Score of A.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/3c/75775.jpg?v=344075325" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
In comparison, its peers like HCA Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hca#NYSE">HCA</a>) and Universal Health Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>) are currently trading at forward 12-month price-to-earnings of 16.43X and 13.91X, respectively.
<h2>Final Verdict: Buy THC Now</h2>
With the stock currently trading at a discount and benefiting from efficiency-enhancing initiatives and favorable industry trends, Tenet appears to have significant growth potential. Investors may consider accumulating more shares, as improving labor market conditions and higher admissions are expected to provide additional support for growth. The upward revisions in estimates are suggesting a promising outlook ahead.
As such, Tenet currently sports a Zacks Rank #1 (Strong Buy).
<a href="https://www.zacks.com/stock/news/2328485/tenet-stock-rises-24-6-in-3-months-is-this-your-buy-signal?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2328485">To read this article on Zacks.com click here.</a>

Tenet Stock Rises 24.6% in 3 Months: Is This Your Buy Signal?

PROCEPT BioRobotics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prct#NASDAQ">PRCT</a>) recently announced FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System. This clearance marks an important achievement for PROCEPT BioRobotics as Aquablation therapy continues its rapid adoption, with more than 400 robotic systems now installed across the United States.
HYDROS Robotic System presents major technological innovations intended for broad market adoption after years of research and development, which the company expects to drive the next stage of its growth.
<h2>More on the HYDROS Robotic System</h2>
Aquablation therapy is&nbsp;a minimally invasive surgical procedure that uses a computer-controlled waterjet to remove prostate tissue, which causes lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
The HYDROS Robotic System represents the next evolution in the delivery of Aquablation therapy, combining cutting-edge technology with user-friendly features designed to deliver better clinical outcomes for patients and healthcare providers.
HYDROS features FirstAssist AI treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is intended to increase productivity, elevate the experience of surgeons and personnel, and provide a more precise and consistent treatment plan for superior clinical results.
HYDROS is likely to move to full market release within the current quarter and be available immediately to hospitals across the United States.
<h2>Key Features of the HYDROS Robotic System</h2>
HYDROS System features FirstAssist AI, which uses advanced image recognition software to precisely detect important anatomy on ultrasound and recommend the best course of action for each patient. It was developed using a library of actual Aquablation therapy treatments.
The system combines digital cystoscopy, next-generation ultrasound imaging, and two high-definition touchscreens to provide simultaneous viewing of ultrasound and cystoscopy pictures and improved anatomy visualization.
The robot executes the surgeon&#39;s treatment plan to remove obstructive tissue while safeguarding vital anatomical structures using a heat-free waterjet. This enables efficient and predictable waterjet execution, standardizing the operative experience across a wide range of prostate sizes and shapes.
<h2>Industry Prospects</h2>
Per a report by Grand View Research, the global BPH treatment devices market, valued at $1.42 billion in 2022, is projected to witness a CAGR of 8.9% from 2023 to 2030.
Technological improvements, increased prevalence of urological illnesses, and growing patient awareness of potential treatment options have all contributed to the expansion of the BPH treatment device market.
The need for BPH treatment devices is also expected to rise soon due to the growing demand for innovative, minimally invasive, non-invasive technologies and Aquablation treatments, which have fewer side effects and quicker recovery times than open surgical techniques.
<h2>Price Performance</h2>
For the year-to-date period, PRCT&#39;s shares have gained 99% compared with the industry&#39;s rise of 9.4%. The S&amp;P 500 increased 17.8% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/62/75041.jpg?v=401489730" />
Image Source: Zacks Investment Research
<h2>Zacks Rank &amp; Stocks to Consider</h2>
PRCT carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2325937/procept-biorobotics-prct-hydros-system-gets-fda-clearance?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2325937">To read this article on Zacks.com click here.</a>

PRCT

PROCEPT BioRobotics' HYDROS System Gets FDA Clearance

CollPlant Biotechnologies&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clgn#NASDAQ">CLGN</a>) and Stratasys Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssys#NASDAQ">SSYS</a>) recently announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin 3D printer.
The study is likely to focus on the ability of implants to grow natural breast tissue and completely degrade over time. As part of the study, 3D printed breast implants consisting of 200cc in the volume of CollPlant&#39;s rhCollagen-based bioinks produced on a Stratasys&#39; Origin printer are to be tested. The pre-clinical study marks a significant step forward in the companies&#39; combined effort to provide patients with care using regenerative medicine instead of traditional implants.
<h3>More on the News</h3>
While CollPlant is a cutting-edge firm in regenerative and aesthetic medicine, creating innovative technologies and products based on its rhCollagen for tissue regeneration and organ production, Stratasys is a leader in polymer 3D printing solutions. Stratasys modified the Origin printer to print the regenerative implants after the two companies announced a collaboration in April 2023. CollPlant is expecting to have initial results from the study in the first half of 2025.
The collaboration between CollPlant and Stratasys is currently focused on developing a bioprinting solution for CollPlant&#39;s breast implants as well as ways to expedite the implant&#39;s construction process. The goal of the study is to evaluate the implants&#39; capacity to stimulate the formation of native breast tissue and eventually degrade entirely.
A substantial share of the total addressable breast implant market is likely to be captured by CollPlant&#39;s innovative breast implants, which are designed to regenerate an individual&#39;s natural breast tissue without triggering an immune reaction. These implants could offer a ground-breaking substitute for reconstructive and cosmetic procedures.
<h3>Industry Prospects</h3>
Per a report by The Brainy Insights, the global breast implant market is estimated to be $3 billion, while breast reconstruction and augmentation procedures represent the second most common plastic surgery procedure performed worldwide.
The most common breast augmentation or reconstruction procedures utilize synthetic breast implantations made of silicone, an artificial substitution for natural regenerated tissue with a risk of complications.
<h3>Price Performance</h3>
For the year-to-date period, CLGN&#39;s shares have lost 24.1% against the industry&#39;s rise of 0.2%. The S&amp;P 500 increased 17.7% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/1d/74826.jpg?v=1569553057" />
Image Source: Zacks Investment Research
<h3>Zacks Rank &amp; Stocks to Consider</h3>
CLGN carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), ABM Industries carries a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2325247/collplant-clgn-stratasys-initiate-study-for-breast-implants?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2325247">To read this article on Zacks.com click here.</a>

CLGN

SSYS

CollPlant, Stratasys Initiate Study for Breast Implants

Cantor Fitzgerald analyst Sarah James reiterates Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Neutral and maintains $219 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Universal Health Servs, Maintains $219 Price Target

McKesson&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>) is witnessing strong momentum, with its shares having rallied 18.3% year to date compared with 0.6% growth of the&nbsp;industry. The S&amp;P 500 Composite has risen 16.5% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Headquartered in San Francisco, CA, McKesson is a healthcare services and information technology company with two operating segments &mdash; Distribution Solutions and Technology Solutions. The first segment distributes branded and generic pharmaceutical drugs, along with other healthcare-related products, on a global basis. It also provides practice management, technology, clinical support and business solutions. The second segment offers enterprise-wide clinical, patient care, financial, supply chain and strategic management software solutions.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/41/74620.jpg?v=129418765" />
Image Source: Zacks Investment Research
<h3>Catalysts Driving Growth</h3>
The rally in MCK&#39;s shares can be attributed to the strength of its robust U.S. Pharmaceutical business. This optimism, led by a solid first-quarter performance and increasing demand for healthcare, is expected to contribute further.
Investors seem to be optimistic regarding the updated earnings guidance. On first-quarter 2025 earnings call, McKesson raised its adjusted earnings per share guidance for fiscal 2025. It now expects adjusted EPS in the range of $31.75-$32.55 (previously $31.25-$32.05), which represents growth of 16-19% from the prior-year level. Revenues are expected to grow 15-17% from the prior-year figure.
The company recorded a significant uptick in its overall top line during the first quarter. This growth was primarily driven by the U.S. Pharmaceutical segment, which saw increased prescription volumes, including higher volumes from specialty products, retail national account customers and GLP-1 medications.
As a result of the major market disruption caused by COVID-19 during the past three years, McKesson has benefited from improved demand across numerous verticals within the medical sector, particularly surgeries. A rebound in demand-driven volumes is also being observed by the company. Sales are also being positively impacted by increasing product pricing.
In April, McKesson launched Project Oasis, an initiative aimed at advancing health equity for at-risk populations in underserved communities. The rising demand for extended and primary care is expected to drive the top line of the Medical-Surgical business in fiscal 2025.
However, a weak first-quarter Medical-Surgical business due to challenges in the primary care channel raises concerns. Although the company has started boosting its operational efficiency and increasing its cost optimization efforts, it will likely take a while to get reflected in the company&#39;s performance.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<h3>Stocks to Consider</h3>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2323842/mckesson-mck-stock-gains-18-ytd-what-s-driving-the-rally?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2323842">To read this article on Zacks.com click here.</a>

Guidance

McKesson Stock Gains 18% YTD: What's Driving the Rally?

Elliot J. Sussman M.D., Board Member at Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>), executed a substantial insider sell on August 15, according to an SEC filing.
What Happened: M.D.'s decision to sell 1,722 shares of Universal Health Servs was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000352915/000112760224022223//Archives/edgar/data/352915/000112760224022223/0001127602-24-022223-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value of the sale is $375,533.
Tracking the Thursday's morning session, Universal Health Servs shares are trading at $221.85, showing a down of 0.0%.
<h3>About Universal Health Servs</h3>
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
<h3>Universal Health Servs: A Financial Overview</h3>
Positive Revenue Trend: Examining Universal Health Servs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.13% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 90.07%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Universal Health Servs's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 4.32.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.77, Universal Health Servs adopts a prudent financial strategy, indicating a balanced approach to debt management.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Universal Health Servs's P/E ratio of 16.3 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.01 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Universal Health Servs's EV/EBITDA ratio at 9.86 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000352915">Check Out The Full List Of Universal Health Servs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Transaction: Elliot J. Sussman M.D. Sells $375K Worth Of Universal Health Servs Shares

In the preceding three months, 16 analysts have released ratings for Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $208.62, along with a high estimate of $267.00 and a low estimate of $162.00. Surpassing the previous average price target of $186.40, the current average has increased by 11.92%.
<img src="https://www.benzinga.com/files/images/story/2024/1723644105_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Universal Health Servs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$267.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$229.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$220.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$256.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$198.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$186.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Announces</td>
<td>Neutral</td>
<td>$198.00</td>
<td>-</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$189.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Universal Health Servs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Universal Health Servs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Universal Health Servs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UHS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Universal Health Servs analyst ratings.</a>
<h2>Unveiling the Story Behind Universal Health Servs</h2>
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
<h3>Universal Health Servs's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Universal Health Servs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.13% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.4%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Universal Health Servs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.54%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Universal Health Servs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.06%, the company showcases efficient use of assets and strong financial health.
Debt Management: Universal Health Servs's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Universal Health Servs Through The Eyes Of 16 Analysts

UBS analyst A.J. Rice maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Buy and raises the price target from $247 to $267.

UBS Maintains Buy on Universal Health Servs, Raises Price Target to $267

Wells Fargo analyst Steve Baxter maintained a Buy rating on Universal Health (UHS – Research Report) on September 6. The company's shares closed la...

Universal Health (UHS) Gets a Buy from Wells Fargo

RBC Capital analyst Ben Hendrix maintained a Hold rating on Universal Health (UHS – Research Report) yesterday and set a price target of $222.00. T...

RBC Capital Keeps Their Hold Rating on Universal Health (UHS)

Universal Health Services announces offering of senior secured notes

Universal Health Services: Stock Has Lots Of Upside Runway

Universal Health Services announces pricing of $1B debt offering via issuance of senior notes

Stocks that are expected to benefit from lower fed funds rate and a softer labor market

Universal Health (UHS) reported robust financial results in the last quarter and raised its full-year outlook. The company's widespread operations, reputation, and high profitability continue to drive growth. So, let's analyze whether it is the right time to buy, sell or hold UHS before its earnings. Read more to find out... Universal Health Services, Inc. (<a href="https://stocknews.com/stock/UHS/">UHS</a>) owns and operates acute care hospitals and outpatient and behavioral health care facilities. The company operates through the Acute Care Hospital Services and Behavioral Health Care Services segments. UHS' solid financial results in the last reported quarter exceeded analysts' expectations.
The company's revenue came in at $3.91 billion, surpassing analysts' estimate of $3.87 billion. Also, its consensus EPS estimate of $4.31 beat the street expectations of $3.32. Further, for the upcoming quarter, analysts expect the company's EPS and revenue for the period (ending September 2024) to increase 45.4% and 9.7% year-over-year to $3.71 and $3.91 billion, respectively.
Moreover, UHS has an impressive earnings surprise history, having topped the consensus revenue and EPS estimates in all of the trailing four quarters.
Further, buoyed by its performance, UHS revised its annual outlook, raising the forecast for net revenues to $15.56 billion - $15.75 billion from the prior range of $15.41 billion - $15.71 billion. Also, it now expects adjusted EBITDA, net of NCI between $2.15 billion and $2.23 billion, up from the prior forecast. And its adjusted EPS is set to range from $15.40 to $16.20.
Shares of UHS have surged 32.3% over the past six months and 84.4% over the past year to close its last trading session at $238.02.
Let's look at factors that could influence UHS' performance in the upcoming months.
Robust Financials
UHS' net <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> increased 10.1% year-over-year to $3.91 billion during the second quarter that ended June 30, 2024. Its income from operations grew 55.8% from the year-ago value to $436.40 million. Adjusted net income attributable to UHS came in at $292.56 million and $4.31 per share, indicating 63.1% and 70.3% growth from the prior year's quarter, respectively.
In addition, the company's adjusted EBITDA net of NCI was $578.70 million, up 35.9% from the prior year's quarter.
Also, UHS' total assets amounted to $14.07 billion as of June 30, 2024, compared to $13.97 billion as of December 31, 2023. A strengthened asset base may positively impact the company's financial health and ability to pursue future growth opportunities.
Solid Historical Growth
UHS' revenue and <a href="https://www.investopedia.com/terms/e/ebitda.asp">EBITDA</a> have grown at respective CAGRs of 6.3% and 3.1% over the past five years. The company's EBIT has increased 2.8% over the same timeframe, while its net income and EPS have improved at CAGRs of 3.1% and 9.3%, respectively.
Also, the company's tangible book value and total assets have grown at CAGRs of 10.4% and 3.7% over the past five years, respectively.
Favorable Analyst Estimates
Analysts expect UHS' revenue for the third quarter (ending September 2024) to increase 9.7% year-over-year to $3.91 billion. The consensus EPS estimate of $3.71 for the same quarter reflects a 45.4% year-over-year improvement. Furthermore, the company has surpassed the consensus revenue and EPS estimates in all of the trailing four quarters, which is impressive.
For the fiscal year ending December 2024, UHS' revenue and EPS are expected to grow 9.9% and 51.4% year-over-year to $15.69 billion and $15.96, respectively. Additionally, Street expects the company's revenue and EPS for the fiscal year 2025 to increase 5.7% and 11.8% year-over-year to $16.59 billion and $17.85, respectively.
High Profitability
UHS' trailing-12-month EBIT margin of 9.60% is 246.9% higher than the respective industry average of 2.77%. Its trailing-12-month levered FCF margin of 4.05% is considerably higher than the industry average of 1.58%.
Furthermore, the stock's trailing-12-month EBITDA margin of 13.40% favorably compares to the industry average of 6.58%. Similarly, its trailing-12-month CAPEX/Sales of 5.70% is 71.5% higher than the industry average of 3.32%.
Low Valuation
In terms of forward non-GAAP P/E, UHS is currently trading at 14.91x, 31.9% lower than the industry average of 21.89x. Also, the stock's forward EV/Sales and EV/EBITDA of 1.33x and 9.52x are considerably lower than the industry average of 3.70x and 13.92x, respectively.
Additionally, the stock's forward Price/Sales and Price/Cash Flow of 1.01x and 8.67x are 73.8% and 46.3% lower than the industry averages of 3.86x and 16.16x, respectively.
POWR Ratings Reflect Promise
UHS' solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. UHS has a B grade for Sentiment, consistent with its optimistic analyst estimates. The stock has a B grade for Value, justified by its lower-than-industry valuation.
Further, it also has a B grade for Growth, which is in sync with its robust financial performance in the last reported quarter.
UHS is ranked #2 in the 10-stock A-rated <a href="https://stocknews.com/category/hospitals/">Medical - Hospitals</a> industry.
Beyond what I have stated above, we have also given UHS grades for Quality, Momentum, and Stability. Get access to all the UHS Ratings <a href="https://stocknews.com/stock/UHS/">here</a>.
Bottom Line
UHS is among the largest and most respected providers of hospital and healthcare services, offering a wide variety of services to patients. Analysts appear bullish about the company's growth prospects, driven by the company's strong market position, wide services range, strong financial performance, and robust profitability.
Further, the industry's inelastic demand offers vast opportunities for the company's future growth.
Given UHS' solid financials, accelerating profitability, and promising growth outlook, this stock could be an ideal buy now.
How Does Universal Health Services, Inc. (UHS) Stack Up Against Its Peers?
While UHS has an overall POWR Rating of A, investors could also check out these other stocks within the A-rated <a href="https://stocknews.com/category/hospitals/">Medical - Hospitals</a> industry with A (Strong Buy) or B (Buy) ratings: Fresenius SE &amp; Co. KGaA ADR (<a href="https://stocknews.com/stock/FSNUY/">FSNUY</a>), Tenet Healthcare Corporation (<a href="https://stocknews.com/stock/THC/">THC</a>), and Encompass Health Corporation (<a href="https://stocknews.com/stock/EHC/">EHC</a>).
For exploring more A and B-rated medical stocks, <a href="https://stocknews.com/category/hospitals/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
UHS shares were trading at $240.52 per share on Monday afternoon, up $2.50 (+1.05%). Year-to-date, UHS has gained 58.28%, versus a 20.61% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/uhs-fsnuy-thc-ehc-should-you-add-universal-health-services-to-your-watchlist/>Should You Add Universal Health Services to Your Portfolio?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Should You Add Universal Health Services to Your Portfolio?

Wells Fargo analyst Steve Baxter maintained a Buy rating on Universal Health (UHS – Research Report) yesterday and set a price target of $255.00. T...

Wells Fargo Reaffirms Their Buy Rating on Universal Health (UHS)

HCA Healthcare: Still A Great Play On Long-Term Growth And Valuation

Stocks with the highest consensus of expected ROE growth, Goldman Sachs says

ACHC

ADBE

ADSK

APTV

AVGO

CRWD

CSCO

CTRA

CTSH

EPAM

FFIV

FSLR

FSNUY

GILD

INTC

JKHY

KEYS

MPWR

NFLX

NTAP

NWSA

ORLY

PANW

PAYC

QRVO

SMCI

TMUS

TRGP

TRMB

TSLA

UBER

WYNN

ZBRA

Press Releases

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT MAY HEALTHCARE CONFERENCES

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2024 FIRST QUARTER FINANCIAL RESULTS

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DIVIDEND

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT THE 45th ANNUAL GOLDMAN SACHS GLOBAL HEALTHCARE CONFERENCE

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DATE FOR SECOND QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2024 SECOND QUARTER FINANCIAL RESULTS, INCREASES 2024 FULL YEAR OPERATING RESULTS FORECAST AND ANNOUNCES $1 BILLION INCREASE TO STOCK REPURCHASE PROGRAM AUTHORIZATION

UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT SEPTEMBER HEALTHCARE CONFERENCES

Offerings

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES OFFERING OF SENIOR SECURED NOTES

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES PRICING OF SENIOR SECURED NOTES

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co

Ardent Health Partners, Inc. Common Stock

Ardent Health Partners

Auna

IMAC Hldgs

Brookdale Senior Living Inc. Common Stock

Brookdale Senior Living

Concentra Group Holdings Parent, Inc. Common Stock

Concentra Group Holdings

Community Health Systems, Inc. Common Stock

Community Health Sys

Encompass Health Corporation Common Stock

Encompass Health

Ensign Group

HCA Healthcare

Inspire Veterinary Partners, Inc. - Class A Common Stock

Inspire Veterinary

Joint

National HealthCare Corporation Common Stock

National Healthcare

PACS Group

Regional Health Properties, Inc. Common Stock

Regional Health Props

Select Medical Holdings Corporation Common Stock

Select Medical Hldgs

Surgery Partners

Sonida Senior Living

SunLink Health Systems, Inc. Common Stock

SunLink Health Systems

Tenet Healthcare Corporation Common Stock

Tenet Healthcare

The Oncology Institute, Inc. - Common Stock

Oncology Institute

US Physical Therapy

RBC Capital

Baird

Cantor Fitzgerald

Goldman Sachs

Universal Health

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>QXO(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>)의 주가는 <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">사모 금융 유치</a>를 발표한 이후 33.37% 상승했다.</li>
<li>아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 S&amp;P MidCap 400에 편입된다는 발표 이후 지난 주에 21.62% 상승했다. 또한 예상보다 나은 2분기 실적을 발표했다.</li>
<li>유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)는 회사가 예상보다 나은 2분기 실적을 발표하고 <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">2024 회계연도 지침을</a> 상향 조정한 후 주가가 17.73% 상승했다.</li>
<li>맨하탄 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고한 후 17.02% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주가는 <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>에 힘입어 15.53% 상승했다.</li>
<li>퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주가는 회사의 분기 실적이 예상보다 높았음을 보고한 후 15.15% 상승했다.</li>
<li>테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)는 예상보다 나은 2분기 재무 결과를 보고한 후 주가가 13.02% 상승했으며, 회사는 FY24 지침을 추정치보다 높이고 3분기 지침을 추정치보다 높게 발표했다. 또한 회사는 <a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">15억 달러 규모의</a> 자사주 매입을 승인했다고 발표했다.</li>
<li>CBRE 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)은 회사가 2024년 목표를 상향 조정한 후 지난 주 주가가 12.99% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 주가는 지난주 12.63% 상승했다. 이 회사는 연간 전망을 <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
<li>다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)의 주가는 회사가 예상보다 나은 2분기 실적을 보고한 후 11.30% 상승하여 더 높게 거래되고 있다.</li>
<li>록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)의 주가는 긍정적인 애널리스트 <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">평가와 강한 2분기 실적</a>에 힘입어 10.72% 상승했다.</li>
</ol>
다음 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일~7월 27일)</a></li>
</ul>
썸네일 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Universal Health Servs

뉴스

에 대한 최신 뉴스 Universal Health Servs (NYSE:UHS) 주식

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌